---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005487"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:24:22.671892+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SAB Bio appoints David Zaccardelli as Chair and Rita Jain as independent director

## Summary
- David Zaccardelli, Pharm.D., appointed Chair of the Board effective January 5, 2026; led Ohtuvayre launch at Verona Pharma.
- Rita Jain, M.D., appointed independent director; brings autoimmune/inflammatory disease drug development expertise.
- Appointments follow RA Capital's nomination rights from July 2025 private placement; CEO Samuel Reich remains on board.
- Company advancing SAB-142, a fully human anti-thymocyte immunoglobulin for type 1 diabetes and autoimmune diseases.

## SEC filing metadata
- accession: 0001193125-26-005487
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312526005487/0001193125-26-005487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312526005487/sabs-20260105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005487
- JSON: https://secwatch.observer/filing/0001193125-26-005487.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.